小檗碱对骨代谢的影响及相关机制研究进展

doi:10.16150/j.1671-2870.2024.06.012

摘要/Abstract

摘要：

骨质疏松症作为我国老年人常见的慢性疾病，伴随人口老龄化进程的加快，其患病率呈逐步上升趋势，流行病学调查显示，中国50岁以上人群骨质疏松症患病率为19.2%，65岁以上为32.0%。这不仅导致老年骨折患者数量不断增加，而且由于民众对该疾病的知晓率和治疗率均较低，使得骨质疏松症的危害尤为突出。小檗碱作为一种传统中药成分，已被证实对多种慢性代谢性及炎性疾病具有疗效，包括糖尿病、肿瘤、心血管疾病、高脂血症、炎症、细菌和病毒感染及骨质疏松症等。在骨代谢方面，无论是对绝经后引发的原发性骨质疏松症，还是糖尿病、肥胖、糖皮质激素应用等多种因素引发的继发性骨质疏松症，小檗碱均展现出一定程度的改善效果。同时在糖尿病、局部感染及炎症状态下的骨缺损修复研究中，小檗碱也表现出强大的骨再生能力。多项体内外研究显示，小檗碱不仅能够通过经典的Wnt/β -catenin、PI3K/AKT、MAPK、AMPK等信号通路来促进成骨细胞的分化和成熟，还可通过抑制 RANKL信号通路，有效抑制破骨细胞的分化和活性。同时，小檗碱还能改善组织氧化应激状态，并通过调节小分子非编码 RNA（miRNA）来对骨代谢进行调控。目前，相关研究多局限于细胞实验与动物实验阶段，距离临床应用仍有较大差距。本文聚焦小檗碱在成骨、破骨等方面的作用机制与研究进展，旨在为深入探究小檗碱治疗骨质疏松症的机制，提供全面且有价值的参考依据。

关键词: 小檗碱, 成骨细胞, 破骨细胞, 骨质疏松症

Abstract:

Osteoporosis is a common chronic disease in the elderly in China. With the acceleration of population aging, the prevalence of osteoporosis is gradually increasing. The prevalence of osteoporosis among people over 50 years old in China is 19.2%, and 32.0% for those over 65 years old. This not only results in an increasing number of elderly patients with fractures but also highlights the significant harm of osteoporosis due to the low awareness and treatment rate As a traditional Chinese medicine ingredient, berberine has been proven to be effective in treating a variety of chronic metabolic and inflammatory diseases, including diabetes, tumors, cardiovascular diseases, hyperlipidemia, inflammation, bacterial and viral infections, and osteoporosis. In terms of bone metabolism, berberine has shown certain improvements in both primary osteoporosis caused by menopause and secondary osteoporosis caused by multiple factors such as diabetes, obesity, and the use of glucocorticoids. Meanwhile, berberine has also shown strong bone regeneration ability in the study of bone defect repair under conditions of diabetes, local infection, and inflammation. Multiple in vivo and in vitro studies have shown that berberine can not only promote the differentiation and maturation of osteoblasts through classical signaling pathways such as Wnt/β‑catenin, PI3K/AKT, APK, and AMPK, but also effectively inhibit the differentiation and activity of osteoclasts by suppressing the RANKL signaling pathway. At the same time, berberine can also improve the oxidative stress state of tissues and regulate bone metabolism by regulating small non‑coding RNAs (miRNAs). This paper focuses on the mechanisms and research progress of berberine in osteogenesis and osteoclastogenesis, aiming to provide a reference for further in‑depth research on the mechanism of berberine in treating osteoporosis.

Key words: Berberine, Osteoblast, Osteoclast, Osteoporosis

中图分类号:

R681

白梦瑶, 孔博, 杨丽惠, 李丽娟, 史燕青, 孙立昊. 小檗碱对骨代谢的影响及相关机制研究进展[J]. 诊断学理论与实践, 2024, 23(06): 634-640.

BAI Mengyao, KONG Bo, YANG Lihui, LI Lijuan, SHI Yanqing, SUN Lihao. Research progress on effects of berberine on bone metabolism and related mechanisms[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(06): 634-640.

图/表 2

参考文献 56

[1]	胡洁玫, 刘晨. 骨质疏松症流行病学概况及相关危险因素[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(42):55-57.
	HU J M, LIU C. Epidemiological profile of osteoporosis and related risk factor[J]. World Latest Med Inf, 2019, 19(42):55-57.
[2]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14):1671-1691. doi: 10.12114/j.issn.1007-9572.2023.0121
	Chinese Medical Association Osteoporosis and Bone Mine-ral Diseases Branch. Guidelines for the diagnosis and treatment of primary osteoporosis(2022)[J]. Chin Gen Pract, 2023, 26(14):1671-1691.
[3]	ZHANG Y, MA J, ZHANG W. Berberine for bone regene-ration: Therapeutic potential and molecular mechanisms[J]. J Ethnopharmacol, 2021, 277:114249.
[4]	YU J L, WANG B W, ZHANG H L, et al. Therapeutic potential of berberine for osteoporosis and its underlying mechanisms: A bioinformatics, network pharmacology, molecular dynamics simulation study[J]. Natural Product Communications, 2022, 17(5):1.
[5]	毛佳乐, 林炳锋, 张晓芹, 等. 基于VDR/GPX4通路探讨小檗碱对去卵巢小鼠骨丢失的抑制作用[J]. 中国中医药科技, 2024, 31(6):983-988.
	MAO J L, LIN B F, ZHANG X Q, et al. Inhibition effects of berberine on bone loss in ovariectomized mice through VDR/GPX4 pathway[J]. Chin J Tradit Med Sci Technol, 2024, 31(6):983-988.
[6]	王燕. 男性代谢状况与骨密度的关系及小檗碱对肥胖雄性大鼠骨代谢的影响[D]. 山东大学, 2020.
	WANG Y. The relationship between male metabolism and bone mineral density and the effect of berberine on bone metabolism in obese male rats[D]. Shandong University, 2020.
[7]	WANG Y, CHEN F, WANG H, et al. Possible therapeutic effects of berberine on bone damage in high-fat diet-induced obese rats[D]. 2020.
[8]	许碧莲, 徐道华, 陈文双, 等. 小檗碱对糖皮质激素性骨质疏松大鼠松质骨和皮质骨的影响[J]. 中国药理学通报, 2011, 27(7):965-970.
	XU B L, XU D H, CHEN W S, et al. Effects of berberine on cancellous and cortical bone in rats induced by glucocorticoid[J]. Chin Pharmacol Bull, 2011, 27(7):965-970.
[9]	ADIL M, MANSOORI M N, SINGH D, et al. Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk[J]. Biomed Pharmacother, 2017, 94:1010-1019. doi: S0753-3322(17)32838-X pmid: 28810524
[10]	LU L, ZHIJIAN H, LEI L, et al. Berberine in combination with insulin has additive effects on titanium implants osseointegration in diabetes mellitus rats[J]. Evid Based Complement Alternat Med, 2015:824259.
[11]	LONDZIN P, KOCIK S, KISIEL-NAWROT E, et al. Lack of berberine effect on bone mechanical properties in rats with experimentally induced diabetes[J]. Biomed Pharmacother, 2022, 146:112562.
[12]	QIN Z, HAN Y, DU Y, et al. Bioactive materials from berberine-treated human bone marrow mesenchymal stem cells promote alveolar bone regeneration by regulating macrophage polarization[J]. Sci China Life Sci, 2024, 67(5):1010-1026.
[13]	吴松, 张文娟, 崔茸茸, 等. 小檗碱对牙周炎大鼠的细胞因子水平、氧化应激和炎症性骨溶解的实验研究[J]. 现代生物医学进展, 2022, 22(5):814-817,851.
	WU S, ZHANG W J, CUI R R, et al. Study of berberine on cytokine levels,oxidative stress and inflammatory osteolysis in rats with periodontitis[J]. Prog Mod Biomed, 2022, 22(5):814-817,851.
[14]	CHEN L, TIAN M, YANG J, et al. Berberine-encapsulated poly(lactic-co-glycolic acid)-hydroxyapatite (PLGA/HA) microspheres synergistically promote bone regeneration with DOPA-IGF-1 via the IGF-1R/PI3K/AKT/mTOR pathway[J]. Int J Mol Sci, 2023, 24(20):15403.
[15]	DUARTE-OLIVENZA C, MONTERO J A, LORDA-DIEZ C I. Effects of berberine on the chondrogenic diffe-rentiation of embryonic limb skeletal progenitors[J]. J Inflamm Res, 2021, 14:5001-5011.
[16]	FAN J, GAO J, CHEN J, et al. Berberine and aspirin prevent traumatic heterotopic ossification by inhibition of BMP signalling pathway and osteogenic differentiation[J]. J Cell Mol Med, 2023, 27(22):3491-3502. doi: 10.1111/jcmm.17919 pmid: 37605888
[17]	HUANG Q, HE W, WENG Y, et al. Berberine inhibits osteogenic differentiation of aortic valve interstitial cells by interfering Smad1/5/8 and NF-κB pathways[J]. Vascul Pharmacol, 2022, 144:106986.
[18]	秦汉, 李玲, 张竞飞, 等. 小檗碱促进骨再生的研究进展[J]. 中国医药科学, 2023, 13(19):45-49.
	QIN H, LI L, ZHANG J F, et al. Research progress of berberine in promoting osteanagenesis[J]. China Med Pharm, 2023, 13(19):45-49.
[19]	李昱林, 俞海鹏, 唐华菁, 等. 小檗碱促进骨再生的机制、安全性及在骨组织工程中的应用[J]. 中国组织工程研究, 2024, 28(35):5702-5708.
	LI Y L, YU H P, TANG H J, et al. The mechanism,safety and application of berberine in promoting bone regeneration[J]. Chin J Tissue Eng Res, 2024, 28(35):5702-5708.
[20]	SOLTANI L, GHANEIALVAR H, ABBASI N, et al. Chitosan/alginate scaffold enhanced with Berberis vulgaris extract for osteocyte differentiation of ovine fetal stem cells[J]. Cell Biochem Funct, 2024, 42(1):e3924. doi: 10.1002/cbf.3924 pmid: 38269507
[21]	SHABAN N Z, KENAWY M Y, TAHA N A, et al. Cellulose acetate nanofibers: incorporating hydroxyapatite (HA), HA/berberine or HA/moghat composites, as scaffolds to enhance in vitro osteoporotic bone regeneration[J]. Polymers (Basel), 2021, 13(23):4140.
[22]	杨玮, 徐道华, 周晨慧, 等. 小檗碱对骨髓间充质干细胞成骨分化的影响[J]. 中国药理学通报, 2010, 26(12):1560-1563.
	YANG W, XU D H, ZHOU C H, et al. Effect of berberine on the osteogenic differentiation of bone marrow mesenchymal cells[J]. Chin Pharmacol Bull, 2010, 26(12):1560-1563.
[23]	WANG D, ZHANG P, MEI X, et al. Repair calvarial defect of osteoporotic rats by berberine functionalized porous calcium phosphate scaffold[J]. Regen Biomater, 2021, 8(3):rbab022.
[24]	ZHANG R, YANG J, WU J, et al. Berberine promotes osteogenic differentiation of mesenchymal stem cells with therapeutic potential in periodontal regeneration[J]. Eur J Pharmacol, 2019, 851:144-150. doi: S0014-2999(19)30123-2 pmid: 30776366
[25]	李善昌, 赵刚, 王飞飞, 等. 小檗碱对小鼠成骨细胞增殖和成骨活性的影响[J]. 黑龙江医药科学, 2016, 39(6):24-26.
	LI S C, ZHAO G, WANG F F, et al. The effects of berbe-rine on the proliferation and osteogenic activity of osteoblasts in mice[J]. Heilongjiang Med Pharm, 2016, 39(6):24-26.
[26]	朱建红, 薛照芸, 黄光业, 等. 四氢小檗碱对过氧化氢致前成骨细胞MC3T3-E1氧化损伤的防治作用及机制探讨[J]. 今日药学, 2018, 28(10):649-654.
	ZHU J H, XUE Z Y, HUANG G Y, et al. Protective Effect of tetrahydroberberine on H₂O₂-induced damage in MC3T3-E1 in vitro[J]. Pharm Today, 2018, 28(10):649-654.
[27]	MING Y, HE X, ZHAO Z, et al. Nanocarrier-assisted delivery of berberine promotes diabetic alveolar bone regene-ration by scavenging ROS and improving mitochondrial dysfunction[J]. Int J Nanomedicine, 2024, 19:10263-10282.
[28]	张帆, 梁清洋, 韩超, 等. Wnt/β-catenin信号通路调控成骨细胞、破骨细胞在骨质疏松中的作用探讨[J]. 中国骨质疏松杂志, 2021, 27(10):1540-1544.
	ZHANG F, LANG Q Y, HAN C, et al. Role of Wnt/β-catenin signaling in the regulation of osteoblasts and osteoclasts in osteoporosis[J]. Chin J Osteoporos, 2021, 27(10):1540-1544.
[29]	张晓, 刘俊瑾, 邵云云, 等. 小檗碱联合绿原酸抗骨质疏松的作用机制[J]. 中国骨质疏松杂志, 2023, 29(7):953-959.
	ZHANG X, LIU J J, SHAO Y Y, et al. Study on the mechanism of the anti? Osteoporosis effect of berberine combined with chlorogenic acid[J]. Chin J Osteoporos, 2023, 29(7):953-959.
[30]	刘岚, 魏松, 张丞, 等. 小檗碱通过PI3K/AKT信号通路调控人牙周膜干细胞的增殖和成骨分化[J]. 中国细胞生物学学报, 2024, 46(3):494-501.
	LIU L, WEI S, ZHANG C, et al. Berberine regulates the proliferation and osteogenic differentiation of human periodontal ligament stem cells through PI3K/AKT signaling pathway[J]. Chin J Cell Biol, 2024, 46(3):494-501.
[31]	周红, 张亚维, 张堃, 等. 人参皂苷Rg3对骨质疏松大鼠骨代谢及肠钙吸收功能的影响[J]. 重庆医科大学学报, 2024, 49(02):141-146.
	ZHOU H, ZHANG YW, ZHANG K, et al. The effect of ginsenoside Rg3 on bone metabolism and intestinal calcium absorption function in osteoporotic rats[J]. J Chongqing Med Univ, 2024, 49(02):141-146.
[32]	XIN B C, WU Q S, JIN S, et al. Berberine promotes osteogenic differentiation of human dental pulp stem cells through activating EGFR-MAPK-Runx2 pathways[J]. Pathol Oncol Res, 2020, 26(3):1677-1685.
[33]	LIU J, ZHAO X, PEI D, et al. The promotion function of berberine for osteogenic differentiation of human perio-dontal ligament stem cells via ERK-FOS pathway media-ted by EGFR[J]. Sci Rep, 2018, 8(1):2848.
[34]	ZHU C Y, XU L, YU W Q. Berberine promotes osteogenic differentiation of rat adipose-derived stem cells through JNK signaling pathway[J]. Shanghai Kou Qiang Yi Xue, 2021, 30(3):258-262.
[35]	周年, 刘波, 徐彭. 氧化应激与骨质疏松症的研究进展[J]. 中国骨质疏松杂志, 2014(12):1485-1489.
	ZHOU N, LIU B, XU P. The research progress of oxidative stress and osteoporosis[J]. Chin J Osteoporos, 2014(12):1485-1489.
[36]	SHAO J, LIU S, ZHENG X, et al. Berberine promotes peri-implant osteogenesis in diabetic rats by ROS-media-ted IRS-1 pathway[J]. Biofactors, 2021, 47(1):80-92.
[37]	ZHOU R, CHEN F, LIU H, et al. Berberine ameliorates the LPS-induced imbalance of osteogenic and adipogenic differentiation in rat bone marrow-derived mesenchymal stem cells[J]. Mol Med Rep, 2021, 23(5):350.
[38]	赵利华, 徐兴才, 杨鑫. 小檗碱联合miR-328-3p对骨髓间充质干细胞增殖和成骨分化能力的影响[J]. 中国药师, 2021, 24(7):262-266.
	ZHANG L H, XU X C, YANG X. Effects of berberine combined with miR-328-3p on the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells[J]. Front Pharm Sci, 2021, 24(7):262-266.
[39]	LIU M, XU Z. Berberine promotes the proliferation and osteogenic differentiation of alveolar osteoblasts through regulating the expression of miR-214[J]. Pharmacology, 2021, 106(1-2):70-78.
[40]	HAN S Y, KIM Y K. Berberine suppresses RANKL-Induced osteoclast differentiation by inhibiting c-Fos and NFATc1 expression[J]. Am J Chin Med, 2019, 47(2):439-455.
[41]	贾鑫林, 毛远青. 去亚甲基小檗碱抑制破骨分化减轻钛颗粒诱导的骨溶解[J]. 医学研究杂志, 2022, 51(12):131-136.
	JIA X L, MAO Y Q. DMB alleviates titanium particle induced osteolysis by inhibiting osteoclast formation[J]. J Med Res, 2022, 51(12):131-136.
[42]	WEI C, SHI M, WANG Z, et al. Epiberberine inhibits bone metastatic breast cancer-induced osteolysis[J]. J Ethnopharmacol, 2024, 327:118039.
[43]	魏鹏, 焦磊, 秦路平, 等. 小檗碱对大鼠骨髓源性破骨细胞的分化及骨吸收功能的影响[J]. 中西医结合学报, 2009, 7(4):342-348.
	WEI P, JIAO L, QIN L P, et al. Effects of berberine on differentiation and bone resorption of osteoclasts derived from rat bone marrow cells[J]. J Integr Med, 2009, 7(4):342-348. doi: 10.3736/jcim20090408 pmid: 19361364
[44]	李梦琦, 吴蔡王尘, 付晶晶, 等. 小檗碱对骨缺损的修复作用及机制研究进展[J]. 中草药, 2024, 55(22):7914-7922.
	LI M Q, WU C W C, FU J J, et al. Repair effect and mechanism of berberine on bone defect[J]. Chin Tradit Herbal Drugs, 2024, 55(22):7914-7922.
[45]	CLARKE B. Normal bone anatomy and physiology[J]. Clin J Am Soc Nephrol, 2008, 3 Suppl 3(Suppl 3):S131-S139.
[46]	宋方茗. 抗骨溶解中药单体筛选及圣草酚、木犀草苷、硫酸小檗碱对破骨细胞作用机制研究[D]. 南宁: 广西医科大学, 2016.
	SONG F M. Screening of monomer of anti-osteolysis chinese medicine and study on the mechanism of eriodictyol, luteolin and berberine sulfate on osteoclasts[D]. Nanning: Guangxi Medical University, 2016.
[47]	CHEN T, AI G, LIANG G, et al. Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway[J]. Biomed Pharmacother, 2024, 174:116523.
[48]	张家胜, 王剑, 郁婷婷. 活性氧簇调控破骨细胞分化的研究进展[J]. 中国骨质疏松杂志, 2023, 29(1):145-150.
	ZHANG J S, WANG J, YU T T, et al. Progress in regulation of osteoclast differentiation by reactive oxygen species[J]. Chin J Osteoporos, 2023, 29(1):145-150.
[49]	吴文玉, 张永萍, 徐剑, 等. 基于线粒体探讨小檗碱作用机制的研究进展[J]. 中医药信息, 2022, 39(11):80-83.
	WU W Y, ZHANG Y P, XU J, et al. Research progress on mechanism of berberine based on mitochondria[J]. Inf Tradit Chin Med, 2022, 39(11): 80-83.
[50]	寇文超, 师建平, 党赢, 等. 由骨免疫学探讨中医药防治绝经后骨质疏松症研究进展[J]. 中国骨质疏松杂志, 2024, 30(8):1215-1218.
	KOU W C, SHI J P, DANG Y, et al. Research progress of prevention and treatment of postmenopausal osteoporosis by traditional Chinese medicine based on bone immuno-logy[J]. Chin J Osteoporos, 2024, 30(8):1215-1218.
[51]	CUI Y, XIE J, CAI L, et al. Berberine regulates bone metabolism in apical periodontitis by remodelling the extracellular matrix[J]. Oral Dis, 2023, 29(3):1184-1196.
[52]	陈长军, 王秋入, 赵鑫, 等. 骨质疏松症的发病机制及临床药物治疗研究进展[J]. 重庆医科大学学报, 2024, 49(10):1031-1038.
	CHEN C J, WANG Q R, ZHAO X, et al. Research advances in the pathogenesis and clinical drug treatment of osteoporosis[J]. J Chongqing Med Univ, 2024, 49(10):1031-1038.
[53]	HE X F, ZHANG L, ZHANG C H, et al. Berberine allevia-tes oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway[J]. Bosn J Basic Med Sci, 2017, 17(4):295-301.
[54]	LU L, HU J, WU Q, et al. Berberine prevents human nucleus pulposus cells from IL‑1β‑induced extracellular matrix degradation and apoptosis by inhibiting the NF‑κB pathway[J]. Int J Mol Med, 2019, 43(4):1679-1686. doi: 10.3892/ijmm.2019.4105 pmid: 30816449
[55]	ZHANG W, SU X, GAO Y, et al. Berberine protects mesen-chymal stem cells against hypoxia-induced apoptosis in vitro[J]. Biol Pharm Bull, 2009, 32(8):1335-1342.
[56]	SUJITHA S, RASOOL M. Berberine coated mannosyla-ted liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3β pathway via upregulating miR-23a[J]. Int Immunopharmacol, 2019, 74:105703.